Sangamo Therapeutics Faces Critical Survival Test as Shares Plunge

Sangamo Therapeutics finds itself navigating perilous financial waters, with its stock experiencing a dramatic 21% decline following disappointing quarterly results and mounting liquidity concerns. The biotech firm now confronts fundamental challenges that threaten its continued existence.

Nasdaq Compliance Deadline Looms

The company’s stock market listing hangs in the balance after Nasdaq granted a 180-day grace period. Sangamo must elevate its share price above the critical $1 threshold by April 27, 2026, or face potential delisting—a devastating scenario for investors. Market reaction has been severe, with shares dropping to $0.46 on November 6 before declining an additional 21.1% by November 9.

Quarterly Performance Reveals Deep Troubles

The third quarter of 2025 proved disastrous for the biotechnology company. Revenue collapsed to just $0.6 million from $49.4 million during the same period last year, primarily due to the expiration of a lucrative collaboration with Genentech.

This catastrophic revenue decline directly impacted the bottom line, resulting in a net loss of $34.9 million. The company reported a loss of $0.11 per share, significantly missing analyst expectations of a $0.03 loss.

Should investors sell immediately? Or is it worth buying Sangamo Therapeutics?

Cash Reserves Dwindle Dangerously

The most immediate threat emerges from Sangamo’s balance sheet, where liquid assets have diminished to just $29.6 million. Current projections indicate these funds will only sustain operations through the first quarter of 2026. A $6 million payment received from Pfizer in October provides only temporary relief, raising urgent questions about whether Sangamo can secure additional financing or strategic partnerships in time to avoid collapse.

Pipeline Assets Offer Glimmer of Hope

Despite the financial turmoil, Sangamo’s development pipeline contains several promising candidates that could potentially reverse its fortunes:

• ST-920 for Fabry Disease: The FDA has confirmed eligibility for accelerated approval, with initial study data showing positive outcomes
• ST-503 for Chronic Pain: Patient recruitment is underway, with initial treatments scheduled to begin soon
• ST-506 for Prion Disease: Preparations for clinical trials in 2026 are currently in progress

The Fabry disease therapy represents the most promising near-term opportunity, with potential approval possible as early as the first quarter of 2026. However, the pressing question remains whether Sangamo possesses sufficient financial runway to reach that milestone.